<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167609</url>
  </required_header>
  <id_info>
    <org_study_id>P001108</org_study_id>
    <secondary_id>PS001108</secondary_id>
    <nct_id>NCT00167609</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DHEA for Myotonic Dystrophy</brief_title>
  <official_title>Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Versailles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Française contre les Myopathies (AFM), Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Versailles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the efficacy and safety of two doses of dehydroepiandrosterone (DHEA) in adults with
      myotonic dystrophy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myotonic dystrophy is an inherited disorder that affects 1 per 8000 adults. The disease is
      characterize by muscular dystrophy, myotonia, cardiac disorders, cognitive function
      impairment, hypersomnia, hair loss, endocrine disorders. Recent small studies suggested that
      DHEA treatment may improve muscle strength in adults with myotonic dystrophy. Thus, the
      current study aims at investigating the safety and efficacy of a prolonged treatment with
      DHEA in adults with myotonic dystrophy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in a Muscle Strength Score between randomization and study week 12</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of myotonia</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appeal score</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth score</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood gas</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in EKG and echocardiography</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerance</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">75</enrollment>
  <condition>Myotonic Dystrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dehydroepiandrosterone 100 and 400 mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myotonic dystrophy (genetically proven)

          -  MDRS score of 3 or 4

        Exclusion Criteria:

          -  Age &lt;18 years or &gt;70 years

          -  Pregnancy or breastfeeding

          -  Poor compliance to treatment and follow up

          -  Inclusion in any other clinical trial

          -  Severe cardiac disease: acute myocardial infarction in the preceding 6 months,
             unstable heart failure, uncontrolled hypertension (systolic blood pressure &gt;180 mmHg
             or diastolic blood pressure &gt;100 mmHg after 10 minutes of rest in the lying position),
             severe arteritis, any past history of thrombose or embolic event, any past history of
             symptomatic arrhythmia)

          -  Chronic renal failure

          -  Chronic liver disease

          -  Long term mechanical ventilation

          -  Any ongoing cancer

          -  Any underlying endocrine disorders

          -  Impaired swallowing

          -  Previous treatment with DHEA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Djillali annane, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique Hôpitaux de Paris - University of Versailles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>martine devillers, MD</last_name>
    <role>Study Director</role>
    <affiliation>AFM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raymond Poincaré Hospital</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pouget</name>
      <address>
        <city>Marseilles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de myologie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Pénisson-Besnier I, Devillers M, Porcher R, Orlikowski D, Doppler V, Desnuelle C, Ferrer X, Bes MC, Bouhour F, Tranchant C, Lagrange E, Vershueren A, Uzenot D, Cintas P, Solé G, Hogrel JY, Laforêt P, Vial C, Vila AL, Sacconi S, Pouget J, Eymard B, Chevret S, Annane D. Dehydroepiandrosterone for myotonic dystrophy type 1. Neurology. 2008 Aug 5;71(6):407-12. doi: 10.1212/01.wnl.0000324257.35759.40.</citation>
    <PMID>18678823</PMID>
  </results_reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>April 5, 2010</last_update_submitted>
  <last_update_submitted_qc>April 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2010</last_update_posted>
  <keyword>myotonic dystrophy</keyword>
  <keyword>hypersomnia</keyword>
  <keyword>dehydroepiandrosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

